Interferon-gamma and Tumor Necrosis Factor-alpha co-stimulation pathway (IFN-gamma/TNF-alpha-UC-MSC pathway)

The Interferon-gamma (IFN-gamma) and Tumor Necrosis Factor-alpha (TNF-alpha) co-stimulation pathway in Umbilical Cord-derived Mesenchymal Stem Cells (UC-MSCs) refers to a synergistic signaling mechanism used to 'license' or 'prime' these cells for therapeutic use. In an inflammatory environment, the simultaneous presence of these two cytokines triggers a phenotypic shift in UC-MSCs, significantly enhancing their immunomodulatory potency (Ren et al., 2008, Cell Stem Cell). This synergy is primarily mediated through the cross-talk between the JAK/STAT1 and NF-kappaB signaling cascades, which leads to a massive induction of Indoleamine 2,3-dioxygenase (IDO1), an enzyme critical for inhibiting T-cell proliferation (Kim et al., 2018, Stem Cells). Additionally, the pathway upregulates inhibitory molecules like PD-L1 and secretes chemokines such as CXCL9 and CXCL10 to recruit immune cells for localized suppression. While this pathway is vital for the efficacy of MSC-based therapies in treating conditions like Graft-versus-host disease (GvHD), it also induces the expression of MHC class II molecules, which may impact the allogeneic safety profile of the cells. Understanding this pathway is essential for optimizing manufacturing protocols to ensure consistent and potent UC-MSC products for clinical applications.

Other names

MSC licensingMSC priming with IFN-gamma and TNF-alphaSynergistic activation of UC-MSCsCytokine-induced MSC activationIFN-gamma/TNF-alpha synergistic signaling

Synergistic activation of the JAK/STAT and NF-kappaB pathways leading to the high-level expression of immunomodulatory factors such as Indoleamine 2,3-dioxygenase (IDO1) and Programmed death-ligand 1 (PD-L1).